Airway acidification impaired host defense against Pseudomonas aeruginosa infection by promoting type 1 interferon β response

Emerg Microbes Infect. 2022 Dec;11(1):2132-2146. doi: 10.1080/22221751.2022.2110524.

Abstract

Airway microenvironment played an important role in the progression of chronic respiratory disease. Here we showed that standardized pondus hydrogenii (pH) of exhaled breath condensate (EBC) of bronchiectasis patients was significantly lower than that of controls and was significantly correlated with bronchiectasis severity index (BSI) scores and disease prognosis. EBC pH was lower in severe patients than that in mild and moderate patients. Besides, acidic microenvironment deteriorated Pseudomonas aeruginosa (P. aeruginosa) pulmonary infection in mice models. Mechanistically, acidic microenvironment increased P. aeruginosa outer membrane vesicles (PA_OMVs) released and boosted it induced the activation of interferon regulatory factor3 (IRF3)-interferonβ (IFN-β) signalling pathway, ultimately compromised the anti-bacteria immunity. Targeted knockout of IRF3 or type 1 interferon receptor (IFNAR1) alleviated lung damage and lethality of mice after P. aeruginosa infection that aggravated by acidic microenvironment. Together, these findings identified airway acidification impaired host resistance to P. aeruginosa infection by enhancing it induced the activation of IRF3-IFN-β signalling pathway. Standardized EBC pH may be a useful biomarker of disease severity and a potential therapeutic target for the refractory P. aeruginosa infection. The study also provided one more reference parameter for drug selection and new drug discovery for bronchiectasis.

Keywords: Bronchiectasis; P. aeruginosa; airway acidification; outer membrane vesicles; type I interferonβ.

MeSH terms

  • Animals
  • Bronchiectasis*
  • Hydrogen-Ion Concentration
  • Interferon Type I*
  • Interferon-beta / genetics
  • Mice
  • Pseudomonas Infections*
  • Pseudomonas aeruginosa / genetics

Substances

  • Interferon Type I
  • Interferon-beta

Grants and funding

This work was supported by the National Natural Science Fund for Distinguished Young Scholar (No. 81925001 to JF Xu), Key Scientific Innovation Project of Shanghai Municipal Education Commission (No. 202101070007-E00097 to JF Xu) and the Innovation Group Project of Shanghai Pulmonary Hospital to JF Xu. The National Natural Science Foundation of China (No. 31730025 to BX Ge).